Combination therapy for treating heart disease

A combination therapy comprising a first amount of an aldosterone antagonist agent and a second amount of a metolazone-related compound, wherein the first amount and second amount together comprise a therapeutically effective amount of the aldosterone antagonist agent and the metolazone-related compound, wherein the aldosterone antagonist agent is spironolactone or eplerenone and the metolazone-related compound is metolazone.

A co-therapy method for treating for treating hypertension, congestive heart failure, or chronic kidney disease, especially of the proteinuric variety, in a subject comprising administering in a substantially simultaneous manner a first amount of an aldosterone antagonist agent and a second amount of a metolazone-related compound, wherein the first amount and the second amount together comprise a therapeutically effective amount of the antagonist agent and the metolazone-related compound.

A co-therapy method for treating hypertension in a subject comprising administering in a substantially simultaneous manner a first amount of an aldosterone antagonist agent and a second amount of a metolazone-related compound, wherein the first amount and the second amount together comprise a therapeutically effective amount of the antagonist agent and the metolazone-related compound.

A co-therapy method for treating congestive heart failure in a subject comprising administering in a substantially simultaneous manner a first amount of an aldosterone antagonist agent and a second amount of a metolazone-related compound, wherein the first amount and the second amount together comprise a therapeutically effective amount of the antagonist agent and the metolazone-related compound.

A co-therapy method for treating for treating chronic kidney disease, especially of the proteinuric variety, in a subject comprising administering in a substantially simultaneous manner a first amount of an aldosterone antagonist agent and a second amount of a metolazone-related compound, wherein the first amount and the second amount together comprise a therapeutically effective amount of the antagonist agent and the metolazone-related compound.